ALX Oncology Inc.

NASDAQ: ALXO · Real-Time Price · USD
0.64
-0.02 (-2.29%)
At close: Aug 15, 2025, 3:59 PM
0.64
0.67%
After-hours: Aug 15, 2025, 04:00 PM EDT

ALX Oncology Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
872K 836K 1.47M 736K
Gross Profit
-872K -836K -1.47M -736K
Operating Income
-142.47M -170.28M -127.44M -83.56M
Interest Income
9.37M 10.65M 4.04M 91.00
Pretax Income
-134.85M -160.81M -123.42M -83.48M
Net Income
-134.85M -160.81M -123.48M -83.46M
Selling & General & Admin
26.09M 28.48M 29.04M 23.39M
Research & Development
116.37M 141.79M 98.4M 60.17M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
142.47M 170.28M 127.44M 83.56M
Interest Expense
1.73M 1.56M 238K 13K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
142.47M 170.28M 127.44M 83.56M
Income Tax Expense
n/a n/a 64K -21K
Shares Outstanding (Basic)
52.17M 42.99M 40.7M 40.31M
Shares Outstanding (Diluted)
52.17M 42.99M 40.7M 40.31M
EPS (Basic)
-2.58 -3.74 -3.03 -2.07
EPS (Diluted)
-2.58 -3.74 -3.03 -2.07
EBITDA
-132.25M -158.4M -121.95M -83.47M
EBIT
-133.12M -159.24M -123.42M -83.47M
Depreciation & Amortization
872K 836K 1.47M 51K